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ABSTRACT: By use of a structure-based computational method for identiﬁcation of structurally novel Janus kinase (JAK)
inhibitors predicted to bind beyond the ATP binding site, a potent series of indazoles was identiﬁed as selective pan-JAK
inhibitors with a type 1.5 binding mode. Optimization of the series for potency and increased duration of action commensurate
with inhaled or topical delivery resulted in potent pan-JAK inhibitor 2 (PF-06263276), which was advanced into clinical studies.
■ INTRODUCTION
Janus kinases, JAKs, are a family of tyrosine kinases comprising
four members (JAK1, -2, -3, and Tyk2). They play a critical role
in both innate and adaptive immunity, since they function as
key transducers in the signaling processes of many cytokine
receptors.1 As such, they have emerged as attractive targets for a
number of inﬂammatory diseases, and numerous inhibitors are
under active clinical development.2 Among these, tofacitinib, 1
(Figure 1) was ﬁrst approved in 2012 by the FDA for the
treatment of rheumatoid arthritis (RA).3 The eﬃcacy and safety
of tofacitinib has been studied in several immune-mediated
inﬂammatory diseases, including rheumatoid arthritis,4 psor-
iasis,5 ulcerative colitis,6 Crohn’s disease,7 psoriatic arthritis,8
and ankylosing spondylitis.9
By use of JAK enzymatic assays run at physiologically
relevant 1 mM ATP concentration, tofacitinib displays
selectivity for JAK1 inhibition, although it also inhibits JAK3
(3-fold weaker) and JAK2 (5-fold weaker). In a cellular settting,
tofacitinib preferentially inhibits signaling by heterodimeric
cytokine receptors that associate with JAK3 and/or JAK1 with
functional selectivity over cytokine receptors that signal via
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Figure 1. Structures of tofacitinib (1) and novel pan-JAK inhibitor (2).
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pairs of JAK2. For example in human whole blood assays,
tofacitinib inhibits IL-15, IFNα, and IL-6 signaling with IC50
values between 35 and 80 nM, whereas the IC50 for JAK2
dependent EPO signaling was ∼300 nM. Given the role of
JAK2 dependent EPO signaling in red blood cell production,
reduction in hemoglobin levels was observed at higher doses
with tofacitinib in clinical trials.2 Despite this, the functional
selectivity for cytokine inhibition for EPO signaling has proven
to be manageable at clinical doses that provide beneﬁt to
rheumatoid arthritis and psoriasis patients without reducing
hemoglobin.4a,10
There are a number of JAK inhibitors in clinical development
that have varying selectivities within the JAK family. In a
cellular setting the advanced candidates preferentially inhibit
JAK1 dependent cytokines, including the γ-common chain
cytokines, interferons, and IL-6.2 Since tofacitinib and other
JAK inhibitor advanced clinical candidates preferentially inhibit
JAK1-dependent cytokines, little clinical diﬀerentiation is
expected. To further improve upon the therapeutic potential
of JAK inhibition in general, a greater degree of selectivity over
systemic JAK2 inhibition and EPO signaling in particular would
be desirable. Besides attempting to produce an inhibitor with
higher selectivity among the JAK family, an alternative
approach for certain diseases would be to target JAK inhibition
directly at the site of action in the relevant organ of interest
while avoiding widespread systemic JAK inhibition. Herein we
describe the design and development of a novel and potent
pan-JAK inhibitor 2 (PF-06263276, Figure 1),11 suitable for
inhaled or topical administration as an organ targeted therapy.
Compound 2 has the potential to treat inﬂammatory diseases of
the lungs (such as COPD)12 and skin (such as mild-to-
moderate psoriasis)5a with negligible systemic JAK inhibition.
■ RESULTS AND DISCUSSION
Following our previously described concept of “inhalation by
design”,13 we sought to design a JAK inhibitor that fulﬁlled the
following criteria: (1) high potency to minimize dose size, given
the limits of dose sizes of typical dry powder inhalation (DPI)
devices (<1 mg drug product) and to minimize the percentage
of active ingredient required in topical formulations, (2) high
selectivity for the JAK family of kinases versus the rest of the
kinome, (3) low systemic exposure and high metabolic
clearance to maximize the therapeutic index by targeting drug
only to the site of action (with no potent active metabolites
formed), (4) multiple routes and mechanisms of metabolism to
minimize the potential for any drug−drug interactions, (5)
suitable solid form characteristics to allow for blending with
lactose for use in a DPI device and formulation as a topical
ointment or cream, (6) evidence of long duration of action
(DoA) of JAK inhibition in enzymatic assays (through kinetic
experiments) or cell based assays (through cell wash-out
experiments), to allow for sustained target modulation in vivo.
Given the successful clinical precedent of tofacitinib to
modulate JAK driven disease, our initial tactic was to increase
the lipophilicity in this template to introduce metabolic
instability, with the aim to maintain or improve the signiﬁcant
JAK potency and selectivity typically observed with this
chemotype, while also assaying for evidence of DoA. We
quickly found that a urea linkage could be used in place of the
amide bond in tofacitinib, and this allowed for facile
introduction of lipophilic groups that maintained excellent
JAK potency and selectivity while introducing metabolic
instability. For example 3 (PF-00956980), a useful commer-
cially available JAK inhibitor tool, (Table 1) maintains excellent
JAK potency and has high turnover in human liver microsomes
(HLM).14 The pyrrolidine ring of 3 could be further
substituted with no loss in potency by larger groups containing
phenols, which were introduced to allow for rapid phase II
metabolism of compounds, thus providing a second route of
metabolism. For example 4 (Table 1) has high turnover in both
HLM and HLM UGT assays and increased JAK enzyme
potency relative to compound 3.
Urea 4 was shown to have a suitable crystalline solid form
and acceptable thermodynamic solubility (20 μg/mL) to meet
our initial compound criteria; however in a number of diﬀerent
assay formats we could not demonstrate evidence for signiﬁcant
DoA with this compound nor with any others within this
chemotype. To investigate enzyme inhibition kinetics, we used
a continuous JAK3 dilution recovery assay using microﬂuidic
mobility shift assay technology.15 Both tofacitinib 1 and urea 3
showed no evidence of slow-oﬀset from JAK3 in this assay,
while 4 showed an oﬀset rate of 0.024 min−1 that translated to a
T1/2 of approximately 28 min. In a PBMC cell-based assay we
could measure inhibition of the cellular pSTAT5 response to
Table 1. Potency and in Vitro Metabolic Stability Data for Tofacitinib Analogues 3 and 4
IC50
a (nM)
compd JAK1 JAK2 JAK3 Tyk2 HLMb ((μL/min)/mg protein) HLM UGTc ((μL/min)/mg protein)
3 37.5 123.6 139.3 1632.2 82 <3.5
4 2.3 21.2 34.1 958.6 131 >200
aCompounds were routinely assayed using Caliper microﬂuidic assays for their potency of inhibition of phosphorylation of a peptide substrate by the
appropriate JAK enzyme at 1 mM ATP concentration. All IC50 values reported represent geometric mean values of a minimum of three
determinations. bCompounds were routinely assessed for metabolic stability in human liver microsomes (HLMs). cCompounds were assessed for
phase II glucuronidation in HLM by including the microsomal activator Brij58 and cofactor uridine diphosphate glucuronic acid (UDPGA) and
excluding the cytochrome P450 dependent cofactor NADPH.
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IL-2 stimulation with 3 and 4 giving IC50 values of 27 nM and
343 nM, respectively. Using this assay, we investigated cellular
DoA by incubating compounds for 1 h at 10-fold the IC50,
washing cells extensively, and then monitoring recovery of the
cellular pSTAT5 response to IL-2 stimulation over time. Both 3
and 4 showed no sign of pSTAT5 inhibition in this assay
immediately following cell washing. Assessing these data
together, we did not view these compounds as having
signiﬁcant potential to show clinical duration of action as
inhaled or topical agents in vivo, and thus we sought an
alternative chemical series.
Examination of overlaid X-ray crystal structures of tofacitinib
1 and 4 bound to JAK2 (Figure 2) shows that they both adopt
the same “type-1” inhibitor binding mode with the methionine
gatekeeper residue ﬂanking the back of the pocket in both
cases.16 The larger molecule 4 shows some displacement of the
glycine rich P-loop of the kinase relative to tofacitinib, although
as demonstrated by our data, this binding mode does not
appear to result in any signiﬁcant kinetic advantage, likely due
to high ﬂexibility of the protein in this region.
It has been well documented by us and others that certain
kinase inhibitor binding modes appear to be correlated to slow-
oﬀset binding kinetics, in particular the “type 2” inhibitor
binding mode.13c,16 This binding mode results in a portion of
the inhibitor binding at a remote distance from the hinge
binding motif, behind the gatekeeper amino acid, into an
induced “back pocket” of the kinase, resulting in signiﬁcant
movement of the DFG portion of the activation loop and
stabilization of an inactive form of the kinase. In order to ﬁnd a
JAK inhibitor series with evidence of DoA in enzyme kinetics
and cell based experiments, we sought to leverage our internal
database of kinase X-ray cocrystal structures, along with kinase
cocrystal structures available from the PDB,17 to identify a
subset of kinase inhibitors with the potential to bind behind the
gatekeeper residue and to screen this subset for potency against
the JAK kinases.
Using approximately 2500 in-house kinase inhibitor crystal
structures, together with approximately 1500 additional
structures available from the PDB, we computationally
collected and aligned all structures into a common orientation.
A computational triage was then performed to identify any
inhibitor templates that were predicted to bind to the hinge
region of the kinase and within 2 Å of the methionine
gatekeeper residue in JAK3. We reasoned that any compounds
found to be potent JAK inhibitors from this selection would
likely bind in a manner necessitating a conformational change
in the kinase, placing binding elements in the back pocket of
the kinase, potentially leading to slower oﬀset kinetics. This
screening eﬀort resulted in the discovery that the indazole-
phenol 5 (Table 2), a compound in our corporate collection
from a previous research program,18 is a potent pan-JAK
inhibitor with IC50 values of <1 nM to 10 nM against the JAK
kinase family at 1 mM ATP concentration. 5 displayed an
enzymatic kinetic oﬀset rate of 0.006 min−1 that translated to a
T1/2 of approximately 114 min for JAK3. It also showed a
signiﬁcant time dependent inhibition of the cellular pSTAT5
response to IL-2 stimulation following compound incubation
and cell washing, with a T1/2 of 6.5 h.
We were pleased to ﬁnd that an X-ray crystal structure of 5
bound to JAK2 (Figure 3) showed a novel binding mode for
Figure 2. Overlaid X-ray cocrystal structures illustrating binding mode
of tofacitinib (1) (PDB entry 3LXK) and 4 (PDB entry 5TQ7) bound
to JAK2.
Table 2. Proﬁle of Indazole-phenol 5
IC50
a (nM)
compd JAK1 JAK2 JAK3 Tyk2 HLMb ((μL/min)/mg protein) HLM UGTc ((μL/min)/mg protein)
5 0.4 2.2 8.3 9.1 35 49
aCompounds were routinely assayed using Caliper microﬂuidic assays for their potency of inhibition of phosphorylation of a peptide substrate by the
appropriate JAK enzyme at 1 mM ATP concentration. All IC50 values reported represent geometric mean values of a minimum of three
determinations. bCompounds were routinely assessed for metabolic stability in human liver microsomes (HLMs). cCompounds were assessed for
phase II glucuronidation in HLM by including the microsomal activator Brij58 and cofactor uridine diphosphate glucuronic acid (UDPGA) and
excluding the cytochrome P450 dependent cofactor NADPH.
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the JAK kinases, compared to the previously observed type-1
binding mode observed with tofacitinib. The methionine
gatekeeper residue moved approximately 4.3 Å from the
known type-1 binding mode orientation, allowing the phenolic
portion of the molecule to bind behind the gatekeeper in an
induced back pocket. The indazole-benzimidazole portion of
the molecule forms three hydrogen bonding interactions with
the hinge region of the kinase, while the phenol group makes
two hydrogen bonding interactions in the back-pocket, with the
α-Glu (E898) of the C-helix and the backbone NH of the Phe
(F995) of the DFG motif. The ethyl group of the phenol ring
occupies the lipophilic space left by movement of the
methionine side chain and helps induce a twist across the
biaryl bond to the indazole ring. It is interesting to note that
despite signiﬁcant binding in the backpocket and the
movement of the gatekeeper methionine, the DFG motif has
not moved signiﬁcantly and that this structure does not
represent a type-2 binding mode. Similar binding modes have
been described previously for other kinases as type 1.5.19 On
the basis of this binding mode, combined with evidence of
slower oﬀset kinetics and more signiﬁcant cellular DoA, we
chose to pursue 5 as an alternative lead for the program.
Considering 5 as a lead, it already fulﬁlled our JAK enzyme
potency requirements and displayed signiﬁcant DoA in both
enzyme and cellular assays. However, the aqueous solubility of
5 was very poor, to the extent that an accurate measurement
could not be determined. In addition, despite a signiﬁcant
increase in lipophilicity compared to the tofacitinib series,
turnover in HLM was only modest, where high metabolism was
desired. It was however of signiﬁcant promise that the molecule
already contained a phenol group which brought modest
turnover in an in vitro assay (HLM UGT) which contained
cofactors for phase 2 glucuronidation. Given the apparent
importance of the hydrogen bonding interactions of the phenol
group in binding to JAK, we postulated that any phase 2
metabolites of the phenol group (for example the glucuronide
or sulfate) would be largely inactive as JAK inhibitors, thus
greatly reducing any liability from systemic JAK inhibition of
potential circulating metabolites. The cross-kinase promiscuity
(Figure 4) appeared less optimal for 5, compared to the
tofacitinib chemotype, as it inhibited 9 of 35 additional kinases
at the ATP Km concentration in a screening panel with >50%
inhibition at 1 μM compound concentration, although only one
of these (ZC1/HGK, also known as MAP4K4) was inhibited at
>85%.
Initial structure−activity relationships (Table 3) were
investigated around the phenol ring in order to probe for
improvements in JAK kinase potency and selectivity, as well as
to increase the overall metabolic rate. We employed enzymatic
assays for each JAK kinase at 1 mM ATP concentration rather
than at the Km concentrations to gain a better understanding of
compound potency and selectivity under more physiologically
relevant conditions.20 In addition assays in primary PBMC cells
were used to measure inhibition of the pSTAT5 response to IL-
15 for cellular DoA, as well as inhibition of the IFNγ response
to IL-2 for potency assessment.
The location of the phenol OH group was shown to be
preferred in the para position to the biaryl linkage, as the
equivalent meta phenol 6 was a signiﬁcantly weaker inhibitor
against JAK enzymes and in the PBMC cellular assay. This is
consistent with the observed X-ray cocrystal structure of 5
where the two hydrogen bonds to the para phenolic OH group
appear to be close to optimal distances. Not surprisingly,
removal of the OH group or methylation to provide a para
methoxyl group resulted in signiﬁcant loss in potency (data not
shown). Increasing the size of the substituent on the phenol
ring to either an isopropyl or n-propyl group (7 and 8) resulted
in a drop in both enzyme and cellular potency, while increasing
the size of this group still further led to even more signiﬁcant
Figure 3. X-ray cocrystal structure of 5 bound to JAK2 (PDB entry
5TQ3) overlaid on protein from cocrystal with 4 to illustrate
movement of the methionine gatekeeper residue. Numbers correspond
to hydrogen bonding distances in angstroms.
Figure 4. Heat map showing kinase inhibition proﬁle of 5 dosed at 1 μM against a panel of 36 kinases at the ATP Km concentration. Colors
correspond to % inhibition of a given kinase as per the color legend shown.
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loss in potency (data now shown). The presence of the ethyl
group was found not to be an essential feature for good potency
against JAK kinases, as a number of compounds without the
ethyl group showed good enzyme and cellular potency.
However, these compounds all had far poorer kinase selectivity
(data now shown). This suggests that an ethyl substituent is
close to the optimal size for a group at this position to maintain
good potency while also providing the beneﬁt of improved
kinase selectivity. Consistent with this observation, a methoxyl
group was also well tolerated at this position, as in 9, albeit with
some loss in potency compared to 5.
At this point we also explored adding groups such as chloro,
cyano, and ﬂuoro adjacent to the phenolic OH group in an
attempt to modulate its glucuronidation rate by acidiﬁcation.13b
However, to maintain good JAK potency, only ﬂuoro groups
were found to be well tolerated in these positions (10 and 11),
with only a small loss in potency compared to 5. This is again
consistent with the observed binding mode as these positions
lie in very close proximity to the protein surface, allowing only
for a small atom to be substituted. It appears as though the
position para to the ethyl group has slightly more space in the
X-ray structure, which is reﬂected in the better cell potency
observed for 11 over 10. Interestingly, the ﬂuoro substitution
para to the ethyl group also resulted in improved kinase
selectivity, as 11 inhibited only 3 kinases of a panel of 36 at
>50% at 1 μM concentration, with only JAK3 (other JAK
family members were not present in the screening subset) in
the panel being signiﬁcantly inhibited at >85% as expected
(kinase heat maps for a number of key analogues can be found
in the Supporting Information). Gratifyingly, this change also
dramatically increased the glucuronidation rate for 11, which
showed a turnover rate in the HLM UGT assay of >360 (μL/
min)/mg protein. This was not the case for 10, which showed
no increase in glucuronidation rate (46 (μL/min)/mg protein)
versus 5, despite the two phenols 10 and 11 having very similar
calculated pKa values. Clearly structural eﬀects around the
Table 3. SAR around Phenol Ring: JAK Kinase Potency and Selected Cellular Potency Data
aCompounds were routinely assayed using Caliper microﬂuidic assays for their potency of inhibition of phosphorylation of a peptide substrate by the
appropriate JAK enzyme at 1 mM ATP concentration. All IC50 values reported represent geometric mean values of a minimum of three
determinations. nt denotes “not tested”. bCellular potency was routinely assayed in peripheral blood mononuclear cells (PBMCs) measuring
inhibition of interferon γ (IFNγ) release following stimulation with interleukin 2 (IL2). All IC50 values reported represent geometric mean values of a
minimum of three determinations.
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phenol as well as acidiﬁcation are important contributing
factors for overall glucuronidation rates. Fluorophenol 11 also
showed good DoA in our cellular wash-out assay, inhibiting the
pSTAT5 response with a T1/2 of 3.5 h, consistent with the
earlier observation for compounds in this series. However,
aqueous solubility was again shown to be low and an accurate
value could not be measured in a thermodynamic solubility
assay. In addition, we could not formulate these molecules
successfully for in vivo eﬃcacy evaluation when attempting to
use solution dosing via the inhaled route. While indazole-
benzimidazoles such as 11 showed some promise to meet our
criteria, they were clearly not soluble enough to be considered
for dosing via the inhaled route, although useful SAR
information had been gained. Moving forward, we needed to
address the poor solubility while maintaining the excellent
potency and encouraging DoA of this series.
In an attempt to improve compound solubility while
maintaining an otherwise favorable proﬁle, we sought to reduce
the overall aromatic ring count in our series.21 SAR
investigations in this series were carried out using the
nonﬂuorinated phenol template. Truncating the benzimidazole
back to imidazole 12 (Table 4) resulted in no loss of potency in
both kinase enzymes and cell based assays. Encouragingly, in
addition to excellent potency, we could also see an improve-
ment in thermodynamic solubility (4.1 μM) measured from a
crystalline solid sample of 12 in water buﬀered at pH 7.4. Not
surprisingly, truncating further to remove the imidazole
completely (R = H) resulted in signiﬁcant loss of potency
given that a key H-bonding interaction with the hinge motif of
the kinase had been removed (data not shown). Alternative
heterocycles that maintained an H-bonding interaction with the
hinge motif, through either an N−H group or aromatic C−H
group, in general showed good enzyme inhibition potency but a
reduced cellular potency relative to imidazole 12. Further
truncation of the imidazole to the amide functionality, as in
primary amide 13 and methylamide 14, maintained the
excellent potency proﬁle while providing a further improve-
ment in solubility (15 μM and 14 μM, respectively, measured
from crystalline solid samples in water buﬀered at pH 7.4).
Methylamide 14 in particular showed an excellent kinase
selectivity proﬁle with only JAK3 out of a panel of 36 kinases
inhibited at >50% at 1 μM concentration. An X-ray cocrystal
structure of primary amide 13 binding to JAK2 (Figure 5)
showed the expected binding mode for the series, with three
key hydrogen bonds in a donor−acceptor−donor motif from
the indazole N−H and lone pair and N−H of the amide to the
hinge region of the kinase, as well as the two hydrogen bonds
from the phenol group to the back pocket residues as noted
previously. Not surprisingly, the dimethylamide 15 showed
signiﬁcant loss of potency, consistent with the requirement for
the amide N−H hydrogen bonding interaction with the kinase.
However, despite adopting the same binding mode as the
indazole-benzimidazole 5, none of these potent and more
soluble truncated compounds showed a signiﬁcant DoA in our
cellular assay nor signiﬁcant slow oﬀset in the kinase kinetic
assay. Subsequent compounds that maintained good DoA (vide
infra) suggested that additional interactions between the ligand
and kinase protein have been lost with this series of smaller
amide compounds, leading to the loss of DoA.
We reasoned that further binding potency and improved
DoA could be achieved by expanding the amide series into the
pocket occupied by the benzimidazole group in our initial lead
5 while maintaining improved solubility. Of a number of larger
amide analogues prepared, we found that only those made from
aromatic amines, for example 16 (Table 4), maintained any
reasonable kinase inhibition potency. Upon inspection of the X-
ray crystal structure of 16 bound to JAK2 (Figure 5), it is clear
that the region of the kinase where the amide heterocyclic
group is bound is restricted in size by a triad of surrounding
amino acids, Leu-855, Tyr-931, and Gly-935. We found that
amides substituted with a methyl group (as in 14) or a planar
group (as in 16) were tolerated in this position, allowing access
through the Leu-Tyr-Gly triad of amino acids to the more open
space beyond the hinge region. Heterocyclic amide 16 showed
reasonable JAK inhibition potency in both enzymatic and
cellular assays, as well as signiﬁcant DoA in our cellular wash-
out assay, with a T1/2 of approximately 4.5 h. In addition, kinase
selectivity for this compound was good, with only 2 kinases
(besides JAK3) in a panel of 36 kinases showing >50%
inhibition at 1 μM concentration. Solubility for amide 16, along
with most other larger heterocyclic amides prepared, although
improved over 5, was however found to be poor (0.5 μM).
Even though we had reduced the aromatic ring count relative to
5, amide 16 is still a rather planar molecule where crystal
Table 4. Replacements for Benzimidazole: JAK Kinase
Potency, Cellular Potency and Solubility Data
aCompounds were routinely assayed using Caliper microﬂuidic assays
for their potency of inhibition of phosphorylation of a peptide
substrate by the appropriate JAK enzyme at 1 mM ATP concentration.
All IC50 values reported represent geometric mean values of a
minimum of three determinations. bCellular potency was routinely
assayed in peripheral blood mononuclear cells (PBMCs) measuring
inhibition of interferon γ (IFNγ) release following stimulation with
interleukin 2 (IL2). All IC50 values reported represent geometric mean
values of a minimum of three determinations.
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packing forces in the solid state are likely to be signiﬁcant.22 In
addition, chemical stability toward hydrolysis was found to be
less than optimal for the majority of these heterocyclic amides
over a relatively short time (>10% degradation seen after 1−2
days at pH 8.0 at 40 °C), raising concerns for potential solid
form stability and formulation problems in this series. Taken
together, these data prompted us to pursue a related but
ultimately more successful subseries as described below.
We pursued an alternative tactic to improving solubility while
maintaining the overall molecular size and similar shape of the
indazole benzimidazole lead, by increasing the sp3 carbon count
in our molecule through saturation of the second aromatic ring
of the benzimidazole system.23 The imidazopiperidine motif 17
(Figure 6) serves this purpose, maintaining the donor−
acceptor−donor motif required for hinge binding, as well as
the planarity required to maintain binding through the Leu-
Tyr-Gly triad of the kinase. In addition, the amine functionality
of the piperidine allowed us to further build out from this
portion of the molecule to increase binding aﬃnity and DoA.
Our SAR exploration was carried out using both the
nonﬂuorinated and ﬂuorinated (at R2) phenol templates
(Table 5). The imidazopiperidine was shown to be an eﬀective
replacement for the benzimidazole group in original lead 5,
with amine 18 showing good enzyme and cell potency. Both
amide 19 and sulfonamide 20 groups could be prepared with
no loss in potency, although the amides typically showed
greater cellular potency. This synthetic strategy allowed for a
wide range of substituents to be explored, enabling modulation
of various properties that could increase HLM and to explore
eﬀects on potency, kinase selectivity, and DoA. The methyl and
acetamide analogues (18 and 19) showed improved solubility
over the earlier benzimidazoles as expected (10−20 μM).
However, their kinase selectivity proﬁles were generally much
poorer, with at least 10 of a panel of 36 kinases showing >85%
inhibition for each of these compounds. Larger substituents,
such as benzyl 21 and benzamides 22 and 2, maintained
excellent enzymatic and cellular JAK potency while also
introducing signiﬁcantly higher HLM turnover, in keeping
with their increased lipophilicity. We were pleased to ﬁnd that,
as previously discovered, introduction of a ﬂuorine atom para to
the ethyl group greatly increased the glucuronidation rate for
these compounds. As shown for the ﬂuorinated piperidinyl-
pyrazine 2, the turnover rate in the HLM UGT assay is 129
(μL/min)/mg protein, compared with 17 (μL/min)/mg
protein for the nonﬂuorinated equivalent (compound not
shown). These compounds with larger substituents on the
piperidine ring also showed signiﬁcant cellular DoA, typically
with T1/2 of >6 h.
Fluorinated piperidinyl-pyrazine 2 met all of our in vitro
assay criteria and was selected for more advanced studies.
Overall it demonstrated good JAK potency, kinase selectivity,
metabolic turnover through two diﬀerent routes of metabolism,
as well as suﬃcient solubility in various formulations for in vivo
testing, even though thermodynamic solubility in aqueous
solution was low (∼0.5 μM). In addition, a crystalline solid
form for 2 was found with excellent chemical and physical
stability. Most noteworthy, 2 displayed a very long cellular DoA
with a T1/2 of 9 h in the PBMC cellular wash-out assay.
Proﬁling 2 against a panel of 36 kinases at 1 μM, a
concentration that signiﬁcantly exceeds the JAK cellular and
enzymatic IC50 values at 1 mM ATP, demonstrated that it has
suitable selectivity over non-JAK kinases as only JAK3 was
inhibited more than 85% at this concentration (Figure 7).
An X-ray crystal structure of 2 bound to JAK2 (Figure 8)
showed the expected binding mode as described previously,
with some additional interactions observed with two of the
residues ﬂanking the front pocket. First, the piperidinyl-
Figure 5. Crystal structures of amides 13 (upper picture, PDB entry
5TQ4) and 16 (lower picture, PDB entry 5TQ5) bound to JAK2. The
triad of amino acids restricting exit of more sterically demanding
amides from the binding pocket is illustrated in cyan. Numbers
correspond to hydrogen bonding distances in angstroms.
Figure 6. Benzimidazole to imidazopiperidine transformation, showing
increasing saturation and sp3 count in our lead series.
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Table 5. Imidazopiperidine Replacement for Benzimidazole: JAK Kinase Potency and Selected Cellular Potency Data
aCompounds were routinely assayed using Caliper microﬂuidic assays for their potency of inhibition of phosphorylation of a peptide substrate by the
appropriate JAK enzyme at 1 mM ATP concentration. All IC50 values reported represent geometric mean values of a minimum of three
determinations. bCellular potency was routinely assayed in peripheral blood mononuclear cells (PBMCs) measuring inhibition of interferon γ
(IFNγ) release following stimulation with interleukin 2 (IL2). All IC50 values reported represent geometric mean values of a minimum of three
determinations cCompounds were routinely assessed for metabolic stability in human liver microsomes (HLMs). dCompounds were assessed for
phase II glucuronidation in HLM by including the microsomal activator Brij58 and cofactor uridine diphosphate glucuronic acid (UDPGA) and
excluding the cytochrome P450 dependent cofactor NADPH.
Figure 7. Heat map showing kinase inhibition proﬁle of 2 dosed at 1 μM against a panel of 36 kinases. Colors correspond to % inhibition of a given
kinase as per the color legend shown.
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pyrazine heterocyclic moiety is wrapped alongside and engaged
in a π-stacking interaction with the amide carbonyl groups of
Leu-855 in the glycine rich P-loop, which also bridges through
water to interact with the imidazole ring. Second, the amide
carbonyl in 2 bridges via another conserved water to interact
with Tyr-931. This additional network of binding interactions
might explain the longer DoA observed with this larger class of
compound within this series.
JAK Inhibitory Proﬁle of 2 in Human Whole Blood
(HWB). In order to test functional potency and to provide
insight into the JAK inhibitory proﬁle of 2, studies in human
whole blood investigated inhibition of STAT phosphorylation
induced by a selection of cytokines known to signal through
various combinations of JAK enzymes (Table 6). In each assay
the inhibition by 2 of STAT phosphorylation was measured in a
speciﬁc subpopulation of white blood cells and IC50 values were
determined. Free IC50 values were calculated by taking into
account plasma protein binding, where the fraction unbound in
plasma is 0.001. These data conﬁrmed that 2 is a functional
pan-JAK inhibitor in human whole blood.
Pharmaceutical Properties of 2. Fluorinated piperidinyl-
pyrazine 2 is a lipophilic compound with a cLogP of 4.4 and
log D of 3.9 (measured by a shake ﬂask method). The
molecular weight of the compound is 566 Da, and the
topological polar surface area (TPSA) is calculated to be 126
Å2. The compound contains both a weakly basic imidazole
group with a measured pKa of 4.5 and a weakly acidic
ﬂuorophenol group with a measured pKa of 8.7. Following
extensive screening eﬀorts, including eﬀorts to generate various
salt forms of the compound, a stable neutral nonsolvated
crystalline form was found that could be crystallized directly
from the ﬁnal reaction step to provide a means of isolating the
compound with excellent purity (Figure 9, left-hand panel).
This form has very low hygroscopicity and is chemically stable
both at room temperature and at 40 °C with 75% relative
humidity for up to 6 weeks, underwriting its long-term stability.
The material is also stable to jet milling to provide solid
material with regular and consistent particle size in the
respirable range (∼2 μm).24 The resulting micronized material
(Figure 9, right-hand panel) has been found to be chemically
and physically stable when blended with lactose for up to 4
weeks, demonstrating its suitability for use in a dry powder
inhalation device.
In addition this crystalline material was also amenable to
preparation as a 4% solution in a base formulation typically
used in topical applications to the skin as shown in Table 7.
In Vitro Metabolism and Pharmacokinetic Properties
of 2. Following in vitro incubation of 2 in human hepatocytes,
the major metabolites observed were produced by direct
glucuronidation and P450 metabolism, consistent with the
presence of the ﬂuorinated phenol group functioning as an
eﬀective handle for phase II conjugation. As discussed
previously in relation to the binding mode of 2, these phenol
conjugated metabolites are expected to show no inhibition of
JAK kinases once formed. This metabolic proﬁle was consistent
across rat and dog in in vitro hepatocyte and microsomal
metabolism studies.
The pharmacokinetic properties of 2 were assessed in vivo
and were found to be consistent with its high lipophilicity and
neutral physicochemistry (Table 8). Consistent with the high in
vitro intrinsic clearance values previously described, 2 exhibits
very high unbound clearance in the rat and dog and has an oral
bioavailability of <5% following oral solution administration to
the rat.
On the basis of these human in vitro data and the in vivo rat
and dog pharmacokinetic data, 2 was predicted to be cleared in
humans by glucuronidation and CYP3A4 metabolism, exhibit-
ing low levels of unbound circulating parent following inhaled
or dermal delivery due to high unbound clearance. Due to the
predicted negligible oral absorption and lack of observed
circulating metabolites in animal Pk studies, the potential for
signiﬁcant levels of circulating active metabolites in human was
deemed to be low risk. Therefore, following topical dosing to
either the lung or skin, 2 demonstrated suitable pharmacoki-
netic properties to provide high conﬁdence that it would
demonstrate an organ targeted eﬀect, with negligible systemic
exposure of parent compound and no active circulating
metabolites. On the basis of the multiple routes of metabolism
(P450 and glucironidation) and projected low levels of
unbound exposure in human, the potential for 2 to be either
a victim or perpetrator of a drug−drug interaction was also
deemed to be low.
Biological in Vivo Activity of 2. The in vivo activity of 2
dosed as a solution via the intratracheal (i.t.) route was
demonstrated in a mouse pharmacodynamic model of IL-6
induced pSTAT3 response in the lungs, mediated via the
JAK1/JAK2 mechanism (Figure 10). 2 caused a dose-related
inhibition of the IL-6-elicited increase in lung pSTAT3, giving
an ED50 of approximately 3 μg/animal. For comparison, the
Figure 8. X-ray cocrystal structure of 2 bound to JAK2 (PDB entry
5TQ8).
Table 6. Inhibitory Potency of 2 in Human Whole Blood









IFNα JAK1/TYK2 lymphocytes pSTAT3 0.62 0.62
IL-23 JAK2/TYK2 lymphocytes pSTAT3 4.2 4.2
IL-4 JAK1/JAK3 monocytes pSTAT6 1.8 1.8
IL-6 JAK1/JAK2 monocytes pSTAT3 2.1 2.1
GM-CSF JAK2/JAK2 monocytes pSTAT5 5.2 5.2
aAll IC50 values reported represent geometric mean values of a
minimum of three determinations.
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inhaled corticosteroid, ﬂuticasone propionate, demonstrates an
ED50 of between 3 μg/animal and 30 μg/animal across a variety
of mouse models when dosed i.t.
In vivo activity was also assessed via topical application of 2
to the skin of a mouse ear in a dermal model of IL-23 induced
inﬂammation (Figure 11). IL-23 is known to be a major driver
of psoriasis pathology mediated via the JAK-STAT pathway.25
For mice ears treated topically with 2 as a 4% solution, a
signiﬁcant reduction of ear swelling (48%) was observed over a
period of 11 days following multiple IL-23 injections in the ear,
consistent with inhibition of the JAK2/TYK2 pathway. For
compound treated mice, swelling typically occurred to less than
50 μm, while ears of control mice receiving IL-23 injections
with no compound treatment typically swelled to over 100 μm.
Proof of organ targeted JAK inhibition in the lung versus
systemic JAK inhibition was shown by comparison of lung
pSTAT3 inhibition to systemic pSTAT5 inhibition following i.t.
dosing of 2 (Figure 12). 2 inhibited phosphorylation of STAT3
in the lung following IL-6 stimulation by 100% at doses of 10
μg and above. In contrast, a 10 μg dose resulted in no inhibition
of STAT5 phosphorylation in the blood following ex vivo GM-
CSF stimulation, while a 100 μg resulted in less than 50%
inhibition. These data provide evidence that 2 exerts
signiﬁcantly greater eﬃcacy in the lung compared to within
the blood following i.t. administration, and this is consistent
with very low systemic exposures expected when considering
the pharmacokinetic properties of 2.
Figure 9. SEM images of solid 2 following crystallization (left-hand panel) and subsequent micronization (right-hand panel).








Table 8. In Vivo Rat and Dog Plasma Pharmacokinetic Data of 2 after Intravenous (iv) and Oral (po Dosing
species dose (mg/kg) Cl (mL min−1 kg−1) Clunbound
c (mL min−1 kg−1) Vss
b (L/kg) terminal T1/2
b (h) oral bioavailability (%)
rat iv 0.5 48 >48000 0.8 2.1
rat po 1 <5
dog iv 0.1a 18 >18000 1.0 2.0
a30 min infusion. bParameters from iv PK proﬁle. cPlasma protein binding, ≥99.9%.
Figure 10. Eﬀects of intratracheal administration of 2 on IL-6 (i.t.)
induced increases in lung phosphorylated STAT3 in the mouse. Left
hand panel represents absolute quantity of phosphorylated pSTAT in
mouse lung. Right hand panel represents the percentage inhibition ±
95% CI calculated from the diﬀerence in geometric mean values
between vehicle/IL-6-treated and vehicle/saline-treated groups.
Figure 11. Eﬀects on mouse ear swelling following IL-23 injection and
treatment with a topical formulation of 2.
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Sustained occupancy of JAK1 after i.t. dosing was also
demonstrated in this model, supporting the potential for an
extended DoA in human lung. The JAK1 occupancy of 2 in
mouse lung was measured by ActivX Biosciences, Inc. (San
Diego, CA, U.S.) following i.t. administration of either 10 μg
(ED80 dose) or 100 μg (maximum inhibitory dose tested) of
2.26 These data suggest that 2 maintains signiﬁcant target
occupancy 4 h postdose for JAK1 (Figure 13), which is
consistent with the long duration of action demonstrated in
human in vitro cell systems. Given that the half-lives of JAK
enzymes in cellular systems have previously been determined to
be 2−3 h,27 the long duration of action that we observe could
be by virtue of tissue retention of the compound in the mouse
lung in the in vivo assays, as well as cellular retention of
compounds in the in vitro assays, in addition to compound
kinetic slow-oﬀ eﬀects on the kinase.
In Vitro and in Vivo Safety Proﬁle of 2. 2 was screened
at 10 μM in a panel of receptors, transporters, enzymes, and ion
channels (CEREP radioligand binding and enzyme inhibition
proﬁle), which demonstrated greater than 50% inhibition of
binding or activity against a small number of targets, namely, 5-
HT7, Abl kinase, acetylcholinesterase, α2B adrenergic receptor,
AurA/Aur2 kinase, KDR kinase, Lck kinase, and Na+ channel
(site 2). However, these activities were observed at multiples of
greater than 100-fold above the projected free systemic plasma
exposures at the maximum clinical lung dose (200 μg), so 2 was
not anticipated to have any consequences at these receptors,
transporters, enzymes, and ion channels if evaluated at clinically
relevant exposures. Furthermore, 2 had no eﬀects on the hERG
potassium current at 1 μM (<1% inhibition). Cough has
historically been a major cause of attrition of inhaled therapies,
so 2 was dosed up to 2 mg in 400 μL of micelle vehicle to the
mouse A delta ﬁber sensory nerve preparation. No nerve
activation was detected with 2, providing evidence that 2
presents a low risk for cough eﬀects. Exploratory 7-day
intravenous toxicology studies were conducted in rats and
dogs to assess risk associated with systemic exposure. There
were no adverse test article-related ﬁndings in any of the
parameters evaluated, with a 36-fold margin achieved in rat over
total plasma AUC based on a projected exposure following a
human clinical lung dose of 200 μg, and a 55-fold margin
achieved in dog plasma AUC. The BioLum Ames bacterial
mutagenicity assay showed no evidence of genetic toxicity with
and without metabolic activation, which was also the case for
the CHO in vitro micronucleus test. Peripheral blood
micronucleus assessment was also made from the rat 7-day
intravenous exploratory toxicology study, and no evidence of
genetic toxicity was observed.
Chemistry: Synthesis of Compounds. The tofacitinib
analogue with phenolic sulfone 4 was prepared as detailed in
Scheme 1, beginning with alcohol 23, whose preparation has
been detailed previously.3a Reaction of the secondary alcohol
with disulfanediyldiphenol proceeded with inversion of stereo-
chemistry, providing the sulﬁde 24, which was oxidized with
potassium peroxymonosulfate to sulfone 4.
Our lead indazole 5 and initial indazole analogues 6 and 9
were available in the Pﬁzer compound collection having been
prepared earlier according to procedures outlined in the patent
literature.18
The synthetic strategy for preparation of the majority of the
indazoles is outlined in Scheme 2. The key reaction involved
formation of a biaryl bond through palladium-catalyzed cross
coupling of indazoles h with protected phenols g to provide key
Figure 12. Eﬀects of i.t. administration of 2 on inhibition of STAT
phosphorylation in the lungs and blood. Data show the eﬀect on IL-6-
induced lung phosphorylated STAT3 or GM-CSF-induced blood
phosphorylated STAT5 with values representing the percentage
inhibition ± 95% CI calculated from the diﬀerence in geometric
mean values between vehicle/IL-6-treated and vehicle/saline-treated
groups: N = 6 (lung) and N = 3 (blood).
Figure 13. Eﬀects of i.t. administration of 2 on JAK1 target occupancy.
Values represent the % occupancy over time with a dose of 10 μg (left-
hand graph) or 100 μg (right-hand graph).
Scheme 1. Synthesis of Tofacitinib Analoguesa
aReagents and conditions: (a) 3,3-disulfanediyldiphenol, Bu3P, toluene, 100 °C, 3 h, 69%; (b) potassium peroxymonosulfate, H2O, THF, IPA, rt, 1
h, 95%.
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intermediate biaryl indazolo-aldehydes f, through which the
majority of targets were prepared. The aldehyde functionality in
f could be directly reacted with diamines to provide imidazole
analogues b or converted to either imidates d or carboxylic
acids e. Imidazopiperidine targets a could be accessed from the
imidate intermediate d, while amide targets c could be accessed
from the carboxylic acid e. For certain targets j, the aldehyde
functionality in h was ﬁrst converted to a benzimidazole
providing i, before palladium catalyzed cross coupling with
phenols g.
The propyl substituted indazolophenols 7 and 8 were
prepared as detailed in Scheme 3. The aldehyde group of
bromoindazole 25 was ﬁrst converted to a benzimidazole group
through reaction with 1,2 diaminobenzene and ammonium
bromide providing 26. Following SEM protection of the N−H
groups, the bromide was converted to a boronic ester aﬀording
27 in good yield. Following bromination of the phenol 28, the
resulting bromide 29, or the commercially available bromide
30, was reacted with 27 in a palladium catalyzed cross-coupling
reaction to provide the ﬁnal targets 7 and 8 in reasonable yield.
The ﬂuorophenol containing targets 10 and 11 were
prepared in a similar manner as detailed in Scheme 4. We
found it preferable to reverse the polarity of the Pd-coupling to
install the boronic ester on the protected phenol portion of the
molecule ﬁrst while maintaining the bromide on the indazole
ring. This arrangement of required reaction partners generally
provided improved yields in the subsequent palladium catalyzed
cross-coupling reaction over the earlier route described in
Scheme 3. Bromination of commercially available
ﬂuoromethoxybenzenes 31 and 32 followed by boronic ester
formation provided the boronic esters 33 and 34. Cross-
coupling with bromoindazole 25 then provided aldehydes 35
and 36. Reaction of the aldehyde group with 1,2 diamino-
benzene and sodium sulﬁte provided the corresponding
Scheme 2. Retrosynthesis for Preparation of Target Indazoles
Scheme 3. Synthesis of Indazolesa
aReagents and conditions: (a) benzene-1,2-diamine, NH4Br, MeOH, 0 °C to rt, 18 h, 52%; (b) NaH, THF, 0 °C, 30 min, then (2-
trimethylsilyl)ethoxymethyl chloride, 2 h, 58%; (c) bis(pinacolato)diboron, (dppf)PdCl2, KOAc, 1,4-dioxane, 100 °C, 15 h, 97%; (d) 4-bromo-3-
(propan-2-yl)phenol 30 or 4-bromo-3-propylphenol 29, PdCl2(PPh3)2, Na2CO3, DME, 150 °C, 1 h, 22−30%; (e) conc HCl, MeOH, 60 °C, 18 h,
56−88%; (f) NBS, MeCN, 0 °C to rt, 18 h, 84%.
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benzimidazoles which were processed to the ﬁnal targets 10
and 11 by removal of the SEM group and deprotection of the
methyl ether.
The imidazole 12 was prepared as shown in Scheme 5. We
found in general a SEM to be a convenient protecting group for
the phenol, allowing for a more straightforward and uniﬁed
ﬁnal deprotection step as compared to a methyl ether. Thus,
the phenol in commercially available aryl bromide 38 was
protected with a SEM group before conversion of the bromide
to a boronic ester, providing 39. Cross-coupling with
bromoindazole 25 proceeded in excellent yield to give aldehyde
37. Conversion of the aldehyde to an imidazole group with
glyoxal and ammonium hydroxide followed by removal of the
SEM groups provided the ﬁnal target imidazole 12.
Amides 13−16 were prepared as detailed in Scheme 6.
Aldehyde 37 was either oxidized, providing the corresponding
carboxylic acid 40 following removal of the SEM groups, or
converted to the nitrile 41 via dehydration of the corresponding
oxime. Standard amide bond forming reactions with the acid 40
provided secondary and tertiary amides 14−16, while the nitrile
41 was treated with basic hydrogen peroxide to provide the
primary amide 13 following SEM group removal.
Our initial synthesis of imidazopiperidine analogues such as
18−20 involved a key palladium catalyzed Stille cross-coupling
reaction between the protected iodoimidazopiperidine 46,
prepared from commercially available imidazopiperidine 45,
and the trimethylstannate derived from iodide 43, which itself
derived from iodoindazole 42 through cross coupling with
boronate ester 39 followed by iodination and SEM protection
(Scheme 7). The Stille cross coupling reaction proceeded in
low to moderate yield to provide the indazole-imidazo-
piperidine 44 following global deprotection. The free amine
group of the unprotected piperidine could then be used
successfully in reductive amination chemistry, amide and
sulfonamide bond formation, providing analogues 18−20.
Scheme 4a
aReagents: (a) NaH, THF, 0 °C 1 h, then (2-trimethylsilyl)ethoxymethyl chloride, 0 °C to rt, 16 h, 99%; (b) 33 or 34, (Ph3P)4Pd, K3PO4, 1,4-
dioxane, H2O, 100 °C, 15 h, 68−71%; (c) benzene-1,2-diamine, Na2SO3, DMA, 100 °C 16 h, 65−70%; (d) conc HCl, MeOH, 60 °C, 16 h, 80−
82%; (e) BBr3, DCM, rt, 72 h, 20−54%; (f) NBS, MeCN, 0 °C to rt, 18 h; (g) bis(pinacolato)diboron, (Ph3P)4Pd, K3PO4, 1,4-dioxane, 100 °C, 15 h,
33−38% over 2 steps.
Scheme 5a
aReagents: (a) NaH, THF, 0 °C 1 h, then (2-trimethylsilyl)ethoxymethyl chloride, 0 °C to rt, 16 h, 99%; (b) 39, (Ph3P)4Pd, K3PO4, 1,4-dioxane,
H2O, 100 °C, 16 h, 94%; (c) glyoxal, NH4OH, MeOH, THF, rt, 16 h, 18%; (d) TBAF, THF, 1,2-diaminoethane, 80 °C, 16 h, 35%; (e) (2-
trimethylsilyl)ethoxymethyl chloride, DIEA, DCM, rt, 18 h, 83%; (f) bis(pinacolato)diboron, (Ph3P)4Pd, K3PO4, 1,4-dioxane, 100 °C, 16 h, 21%.
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An alternative synthetic route (Scheme 8) was used to
prepare additional imidazopiperidine analogues such as 21,
which involved a condensation reaction between imidate 48
and amino acetal 53, followed by cyclocondensation of amidine
intermediate 49. This route provided a facile and more reliable
route to key targets, providing signiﬁcantly higher yields on
scale up and avoiding the use of tin reagents on larger scale.
Imidate 48 was prepared from the commercially available
bromoindazole 25 through initial THP protection and
conversion of the aldehyde to a nitrile group, providing 47.
Palladium catalyzed cross-coupling with the boronate ester 51
and conversion of the nitrile to an imidate using sodium
methoxide furnished 48. The boronate ester itself was prepared
from commercially available ﬂuorophenol 50, which was ﬁrst
brominated in the position para to the phenol, followed by
SEM protection of the phenol and palladium catalyzed
boronate ester formation, providing 51. The requisite amino
acetal 53 was prepared according to a known sequence from
commercially available 4-ketopiperidine 52, a key step in the
sequence being a Neber rearrangement.28 Following con-
densation of imidate 48 and amino acetal 53, cyclo-
condensation of the amidine 49 was carried out under acidic
conditions which also led to successful deprotection of the
SEM and THP groups, providing target amine 21 in excellent
yield.
In order to prepare further amide derivatives of the
imidazopiperidine group, as well as to provide a more uniﬁed
and eﬃcient protecting group strategy, we employed the Boc
protected amino acetal 57 in the condensation reaction with
imidate 48 (Scheme 9). Treatment of the resulting amidine 54
with acid led to cyclocondensation and global deprotection of
all acid labile protecting groups, providing imidazopiperidine 55
in excellent overall yield. The amino acetal 57 was prepared
according to a known sequence involving a Neber rearrange-
ment from commercially available 4-ketopiperidine 56.29
Intermediate 55 was a highly versatile intermediate that could
be prepared on multigram scale following the synthetic
procedures described herein. The piperidine amino group
could be reacted selectively to prepare a range of amides,
sulfonamides, carbamates, ureas, and tertiary amines. Synthesis
Scheme 6a
aReagents and conditions: (a) NaClO2, 2-methylbut-2-ene, NaH2PO4,
tBuOH, H2O, rt, 1 h, 72%; (b) TBAF, THF, 1,2-diaminoethane, rt, 16 h, 41%;
(c) methylamine or dimethylamine hydrochloride, EDC, HOBT, 4-methylmorpholine, DMF, rt, 16 h, 60−63%; (d) 2-methyl-5-aminopyridine,
HATU, TEA, DMAP, DMA, 30 °C, 16 h; (e) (i) hydroxylamine hydrochloride, Et3N, MeCN, 60 °C, 1.5 h; (ii) trichloroacetyl chloride, Et3N,
MeCN, 60 °C, 16 h, 82%; (f) 30% H2O2, KOH, EtOH, rt, 4 h, 82%; (g) TBAF, THF, 1,2-diaminoethane, 60 °C, 3 h, 63%.
Scheme 7a
aReagents: (a) 39, (dppf)PdCl2, K3PO4, DME, H2O, 140 °C, 1 h, 79%; (b) KOH, DMF, rt, 5 min, then I2, rt, 30 min, 84%; (c) NaH, THF, 0 °C 15
min, then (2-trimethylsilyl)ethoxymethyl chloride, 0 °C to rt, 16 h, 40%; (d) (Me3Sn)2, (Ph3P)4Pd, toluene, 80 °C, 16 h, 69%; (e) 46, CuI,
(Ph3P)4Pd, THF, 65 °C, 90 h, 26%; (f) Pd(OH)2/C, H2 200 psi, EtOH, 60 °C, 24 h, 86%; (g) conc HCl, MeOH, 64 °C, 18 h, 100%; (h) CH2O
37% in H2O, NaBH(OAc)3, DIEA, DMF, AcOH, rt, 16 h, 50%; (i) Ac2O or (MeSO2)2O, Et3N, DMF, rt, 16 h, 13−30%; (j) Boc2O, Et3N, DCM, 0
°C to rt, 16 h, 85%; (k) n-BuLi, THF, −78 °C, then I2, 1.25 h, 33%.
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of two key amide analogues is illustrated in Scheme 9. Standard
amide bond coupling conditions using HATU were employed
to couple 55 with commercially available paraﬂuorobenzoic
acid or pyrazine carboxylic acid 58, providing amides 22 and 2
in excellent yields.
■ CONCLUSIONS
We have described our approach to the discovery of a novel
JAK inhibitor 2 that is well suited for inhaled delivery to the
lungs and/or topical delivery to the skin. Our initial eﬀort to
work within our clinically precedented tofacitinib chemical
series produced compounds that met most of the requirements
for our program, but these did not have the key fundamental
property of DoA. This led us to adopt a new approach and use
X-ray crystal structures to guide a targeted screening eﬀort to
ﬁnd JAK inhibitors with novel binding modes. This led to the
discovery of the indazole series of compounds that bound in a
type 1.5 binding mode to JAK and that showed good evidence
of duration of action. We then followed a number of
approaches to improve upon the solubility, kinase selectivity,
and cellular duration of action of this series as described,
leading to the preparation of 2. The in vitro and in vivo
potency, pharmacokinetic and safety proﬁle of 2 demonstrate
that it is potentially well suited for use as an inhaled or topical
therapy to treat inﬂammatory diseases, such as COPD or
psoriasis, through direct administration to the lungs or skin,
while avoiding any systemic-based JAK inhibition. We believe
that this proﬁle may oﬀer an improved safety proﬁle for use in
these disease indications over oral JAK kinase inhibitors, given
the challenges associated with systemic JAK2 inhibition in
particular. The pharmaceutical properties of 2 are suitable for
combination with lactose in a dry powder inhaler, as well as for
use in typical topical formulations. Taken together, this
promising overall proﬁle has led to the nomination of 2 as a
development candidate, an inhaled therapy for COPD, and a
topical therapy for psoriasis. Further information relating to the
research and development of 2 will be reported in due course.
A similar approach to JAK inhibition via the inhaled route
has recently been described,30 as well as a similar approach to
provide soft drug JAK inhibitors for topical use to treat
psoriasis.31
Scheme 8a
aReagents and conditions: (a) 3,4-dihydro-2H-pyran, pTSA, DCM, 0 °C to rt, 16 h, 73%; (b) hydroxylamine hydrochloride, Et3N, MeCN, 60 °C, 3
h, then TFAA, Et3N, MeCN, 0 °C to rt, 2 h, 99%; (c) 51, (Ph3P)4Pd, K3PO4, 1,4-dioxane, H2O, 110 °C, 18 h, 81%; (d) NaOMe, MeOH, rt, 18 h,
100%; (e) 53, AcOH, EtOH, 50 °C, 18 h, 45%; (f) conc HCl, EtOH, rt, 18 h, 100%; (g) conc HCl, EtOH, 65 °C, 18 h, 80%; (h) CuBr2, MeCN, rt,
16 h, 100%; (i) (2-trimethylsilyl)ethoxymethyl chloride, DIEA, DCM, rt, 18 h, 86%; (j) bis(pinacolato)diboron, Pd(dppf)Cl2, KOAc, 1,4-dioxane,
100 °C, 18 h, 100%.
Scheme 9a
aReagents and conditions: (a) 57, AcOH, EtOH, 50 °C, 18 h, 100%; (b) conc HCl, EtOH, rt, 18 h, 88%; (c) 4-ﬂuorobenzoic acid or 58, HATU,
DIEA, DMF, rt, 18 h, 89%;
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■ EXPERIMENTAL SECTION
General Experimental. Unless otherwise indicated, all reactions
were carried out under a nitrogen atmosphere, using commercially
available anhydrous solvents. Thin-layer chromatography was
performed on glass-backed precoated Merck silica gel (60 F254)
plates, and compounds were visualized using UV light, 5% aqueous
potassium permanganate, or chloroplatinic acid/potassium iodide
solution. Silica gel column chromatography was carried out using 40−
63 μm silica gel (Merck silica gel 60). Proton NMR spectra were
measured on a Varian Inova 400 or Varian Mercury 400 spectrometer
in the solvents speciﬁed. Low resolution mass spectra were recorded
on either a Fisons Trio 1000, using thermospray positive ionization, or
a Finnigan Navigator, using electrospray positive or negative
ionization. High resolution mass spectra were recorded on a Bruker
Apex II FT-MS using electrospray positive ionization. All target
compounds were puriﬁed until at least >95% purity as judged by
HPLC utilizing an ELSD detection system.
1H nuclear magnetic resonance (NMR) spectra were in all cases
consistent with the proposed structures. Characteristic chemical shifts
(δ) are given in parts-per-million downﬁeld from tetramethylsilane
using conventional abbreviations for designation of major peaks: e.g., s,
singlet; d, doublet; t, triplet; m, multiplet; br, broad. The mass spectra
(m/z) were recorded with electrospray ionization (ESI). The following
abbreviations have been used for common solvents: CDCl3,
deuterochloroform; DMSO-d6, deuterodimethyl sulfoxide; methanol-
d4, deuteromethanol. Concentration of solutions after reactions and
extractions involved the use of a rotary evaporator operating at a
reduced pressure of ∼20 Torr. LCMS analysis was carried out using
the following conditions. Solvent A: 0.1% formic acid in water. Solvent
B: 0.1% formic acid in acetonitrile. Column: C18 phase Phenomenex
20 mm × 4.0 mm with 3 μm particle size. Gradient: 98−10% A over
1.5 min, 0.3 min hold, 0.2 re-equilibration, 1.8 mL/min ﬂow rate. UV:
210−450 nm DAD. Temperature: 75 °C.
PAINS Analysis. Compounds were examined for known classes of
pan assay interference compounds using an in-house computational
structure ﬁlter based on literature precedent.32 None of the ﬁnal
compounds that were assayed for bioactivity were ﬂagged as being
potential PAINS.
Chemistry. Synthetic Procedures to 2. Additional experimental
procedures for all novel compounds prepared during the course of this
work can be found in the Supporting Information.
2-[6-(2-Ethyl-5-ﬂuoro-4-hydroxyphenyl)-1H-indazol-3-yl]-
1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl-(5-piperidin-1-yl-
pyrazin-2-yl)methanone (2). To a solution of 5-piperidin-1-
ylpyrazine-2-carboxylic acid 58 (10.7 g, 51.8 mmol) in dimethylfor-
mamide (200 mL) were added N,N-diisopropylethylamine (24.6 mL,
141 mmol) and HATU (21.5 g, 56.5 mmol, and the resulting mixture
was stirred at ambient temperature for 10 min before being added
dropwise to a suspension of compound 55 (19.5 g, 47.1 mmol) in
dimethylformamide (200 mL) over 30 min, using a further 75 mL
dimethylformamide to wash the vessel. The reaction mixture was then
stirred at ambient temperature for 18 h. A further portion of 5-
piperidin-1-ylpyrazine-2-carboxylic acid 58 (1.07 g, 5.18 mmol) in
dimethylformamide (40 mL) was treated with N,N-diisopropylethyl-
amine (2.46 mL, 14.1 mmol) and activated with HATU (2.15 g, 5.65
mmol), and the resulting mixture was stirred at ambient temperature
for 10 min before being added to the original reaction mixture which
was then stirred for a further 4 h. The reaction mixture was poured
onto water (1.2 L), and the pH was adjusted to 7 with sodium
hydroxide solution. The resulting suspension was stirred at ambient
temperature for 30 min. The precipitate was collected by ﬁltration,
washed with water (400 mL), and then dried in vacuo. The crude
material was dissolved in ethanol (113 mL) and treated with a 1 M
aqueous solution of sodium hydroxide. The reaction mixture was
stirred at ambient temperature for 18 h. The precipitate was collected
by ﬁltration, washed with a cold solution of 1:3 1 M sodium
hydroxide/ethanol (100 mL), and dried in vacuo. The residue was
dissolved in water (100 mL) and treated with a 10% aqueous solution
of citric acid (10 mL) to adjust the pH to 4. A few drops of 1 M
sodium hydroxide solution were added to bring the pH to 7. The
resulting suspension was stirred at ambient temperature for 1 h and
the solid collected by ﬁltration, washed with water, and then dried in
vacuo to give the title compound 2 (13.86 g, 89%). 1H NMR (400
MHz, DMSO-d6) δ 9.90 (br s, 1H), 8.44 (s, 1H), 8.31 (d, J = 1.17 Hz,
1H), 8.27 (br s, 1H), 7.58 (s, 1H), 7.32 (d, J = 7.42 Hz, 1H), 7.05 (d, J
= 11.72 Hz, 1H), 6.94 (d, J = 9.18 Hz, 1H), 4.96 (br s, 1H), 4.82 (br s,
1H), 4.02 (t, J = 5.37 Hz, 2H), 3.66−3.75 (m, 4H), 2.92 (br s, 2H),
2.42−2.49 (m, 2H), 1.66 (d, J = 4.69 Hz, 2H), 1.58 (d, J = 3.90 Hz,
4H), 1.02 (t, J = 7.52 Hz, 3H). LCMS found 567 [M + H]+. HRMS
calcd for C31H32FN8O2: 567.2627. Found [M + H]
+: 567.2621.
6-Bromo-1-(tetrahydropyran-2-yl)-1H-indazole-3-carboni-
trile (47). To a solution of 6-bromo-1H-indazole-3-carbaldehyde 25
(13.97 g, 61.9 mmol) in dichloromethane (150 mL) was added p-
toluenesulfonic acid (2.36 g, 12.4 mmol), and the mixture was cooled
to 0 °C. 3,4-Dihydro-2H-pyran (8.47 mL, 92.8 mmol) was added
dropwise to the solution, and the reaction was stirred at ambient
temperature overnight. The reaction mixture was diluted with
dichloromethane (200 mL) and washed with a solution of saturated
aqueous sodium hydrogen carbonate (500 mL). The aqueous layer
was re-extracted with dichloromethane (500 mL), and the combined
organic layers were washed with brine (2 × 1 L), dried over anhydrous
magnesium sulfate, and concentrated in vacuo. The crude material was
reﬂuxed in cyclohexane (20 mL) and ﬁltered while hot. The ﬁltrate
was concentrated in vacuo, and the residue was stirred in heptane for
48 h. The resulting solid was collected by ﬁltration to give 6-bromo-1-
(tetrahydropyran-2-yl)-1H-indazole-3-carbaldehyde (13.87 g, 73%).
1H NMR (400 MHz, CDCl3) δ 10.19−10.25 (m, 1H), 8.16 (d, J =
8.59 Hz, 1H), 7.88 (d, J = 0.98 Hz, 1H), 7.46 (dd, J = 1.56, 8.59 Hz,
1H), 5.78 (dd, J = 2.83, 8.69 Hz, 1H), 4.95 (dd, J = 2.64, 4.78 Hz, 2H),
3.96−4.04 (m, 2H), 3.88 (ddd, J = 3.42, 7.32, 11.13 Hz, 3H), 3.74−
3.82 (m, 1H), 3.46−3.57 (m, 3H), 2.48−2.61 (m, 2H), 2.08−2.28 (m,
3H), 1.81−1.95 (m, 4H), 1.71−1.80 (m, 6H), 1.48−1.66 (m, 16H).
LCMS found 309 [M + H]+. To a solution of 6-bromo-1-
(tetrahydropyran-2-yl)-1H-indazole-3-carbaldehyde (60 g, 194
mmol) in acetonitrile (1.5 L) were added triethylamine (68.5 mL,
485 mmol) and hydroxylamine hydrochloride (20 g, 291 mmol). The
reaction was heated at 60 °C for 3 h. The reaction was cooled to 0 °C,
further triethylamine (220 mL, 1.55 mol) was added, and TFAA (109
mL, 776 mmol) was added dropwise. The reaction was allowed to
warm to ambient temperature and stirred for 2 h. Water (2 L) was
added to the reaction mixture, and the resulting solid was collected by
ﬁltration. The solid was dissolved in dichloromethane (1 L), and the
resulting solution was washed with water (2 × 500 mL). The organic
layer was dried over anhydrous magnesium sulfate and concentrated in
vacuo to give the title compound 47 (58.59 g, 99%). 1H NMR (400
MHz, CDCl3) δ 7.93 (d, J = 0.98 Hz, 1H), 7.69 (d, J = 8.79 Hz, 1H),
7.46 (dd, J = 1.56, 8.79 Hz, 1H), 5.76 (dd, J = 2.93, 8.20 Hz, 1H),
3.88−3.96 (m, 1H), 3.71−3.81 (m, 1H), 2.40−2.54 (m, 1H), 2.05−
2.23 (m, 2H), 1.68−1.85 (m, 3H). LCMS found 306 [M + H]+.
6-[2-Ethyl-5-ﬂuoro-4-(2-trimethylsilanylethoxymethoxy)-
phenyl]-1-(tetrahydropyran-2-yl)-1H-indazole-3-carboximidic
Acid Methyl Ester (48). To a solution of 47 (28.5 g, 93 mmol) and
51 (73.8 g, 112 mmol) in 1,4-dioxane (500 mL) was added a solution
of potassium phosphate (59.2 g, 279 mmol) in water (120 mL). The
mixture was degassed with nitrogen, and then tetrakis(triphenyl-
phosphine)palladium (0) (10.8 g, 9.3 mmol) was added. The reaction
mixture was heated at 110 °C for 18 h. The reaction mixture was
concentrated in vacuo, and the residue was redissolved in ethyl acetate
(1 L) and ﬁltered through Arbocel, washing with ethyl acetate (2 ×
500 mL). The combined organic phases were concentrated in vacuo.
The residue was puriﬁed by column chromatography on silica gel,
eluting with 10% ethyl acetate in heptane to give 6-[2-ethyl-5-ﬂuoro-4-
(2-trimethylsilanylethoxymethoxy)phenyl]-1-(tetrahydropyran-2-yl)-
1H-indazole-3-carbonitrile (37.4 g, 81%). 1H NMR (400 MHz,
CDCl3) δ 7.85 (dd, J = 0.78, 8.40 Hz, 1H), 7.62 (d, J = 0.98 Hz, 1H),
7.30 (dd, J = 1.27, 8.30 Hz, 1H), 7.18 (d, J = 8.40 Hz, 1H), 7.15−7.23
(m, 1H), 7.00 (d, J = 11.52 Hz, 1H), 5.82 (dd, J = 2.73, 8.59 Hz, 1H),
5.30−5.35 (m, 2H), 3.94−4.01 (m, 1H), 3.83−3.91 (m, 2H), 3.75
(ddd, J = 3.71, 8.64, 11.86 Hz, 1H), 2.53 (q, J = 7.35 Hz, 2H), 2.12−
2.25 (m, 2H), 1.66−1.89 (m, 3H), 1.11 (t, J = 7.52 Hz, 3H), 1.02 (dd,
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.6b01634
J. Med. Chem. XXXX, XXX, XXX−XXX
P
J = 7.71, 8.88 Hz, 2H), 0.01−0.09 (m, 9H). To a solution of 6-[2-
ethyl-5-ﬂuoro-4-(2-trimethylsilanylethoxymethoxy)phenyl]-1-(tetrahy-
dropyran-2-yl)-1H-indazole-3-carbonitrile (37.42 g, 75.6 mmol) in
methanol (700 mL) was added sodium methoxide (12.21 g, 226.8
mmol), and the reaction mixture was then stirred at ambient
temperature for 18 h. The solvent was removed in vacuo, and the
residue was partitioned between ethyl acetate (1 L) and water (500
mL). The organic layer was washed with water (500 mL), dried over
anhydrous magnesium sulfate, and concentrated in vacuo to give the
title compound 48 (37.26g, 94%). 1H NMR (400 MHz, CDCl3) δ
8.41−8.61 (m, 1H), 8.05−8.12 (m, 1H), 7.50 (s, 1H), 7.14−7.23 (m,
2H), 7.03 (d, J = 11.52 Hz, 1H), 5.76 (dd, J = 2.73, 9.18 Hz, 1H),
4.06−4.12 (m, 3H), 4.00−4.06 (m, 1H), 3.82−3.91 (m, 2H), 3.70−
3.79 (m, 1H), 3.50 (s, 2H), 2.49−2.66 (m, 2H), 2.06−2.25 (m, 2H),
1.63−1.88 (m, 4H), 1.10 (t, J = 7.52 Hz, 3H), 0.97−1.06 (m, 2H),
−0.02 to 0.13 (m, 9H). LCMS found 528 [M + H]+.
2-[2-Ethyl-5-ﬂuoro-4-(2-trimethylsilanylethoxymethoxy)-
phenyl]-4,4,5,5-tetramethyl[1,3,2]dioxaborolane (51). To a
solution of 5-ethyl-2-ﬂuorophenol 50 (76.36g, 545 mmol) in
acetonitrile (2.5 L) was added copper(II) bromide (361.5 g, 1.62
mol). The resulting suspension was stirred at ambient temperature
overnight. The solvent was removed in vacuo, and the residue was
suspended in ethyl acetate (3 L) and ﬁltered through a pad of Arbocel.
The ﬁltrate was washed with water (2 L) and brine (2 L), dried over
anhydrous magnesium sulfate, and concentrated in vacuo to give 4-
bromo-5-ethyl-2-ﬂuorophenol (119 g, 100%). 1H NMR (400 MHz,
CDCl3) δ 7.29 (d, J = 2.34 Hz, 1H), 6.92 (d, J = 9.37 Hz, 1H), 5.21
(br s, 1H), 2.69 (q, J = 7.41 Hz, 2H), 1.22 (t, J = 7.61 Hz, 3H). To a
solution of 4-bromo-5-ethyl-2-ﬂuorophenol (80 g, 365 mmol) in
DCM (1 L) was added N,N-diisopropylethylamine (70 mL, 401
mmol) and (2-trimethylsilyl)ethoxymethyl chloride (71 mL, 401
mmol). The resulting solution was stirred at ambient temperature for
18 h. The reaction mixture was washed with water (1 L), dried over
anhydrous magnesium sulfate, and concentrated in vacuo to yield the
crude product. This material was puriﬁed by silica gel chromatography,
eluting with 30% DCM in heptane to give [2-(4-bromo-5-ethyl-2-
ﬂuorophenoxymethoxy)ethyl]trimethylsilane. (109.8 g, 86%). 1H
NMR (400 MHz, CDCl3) δ 7.25−7.30 (m, 1H), 7.07−7.12 (m,
1H), 5.24 (s, 2H), 3.77−3.85 (m, 2H), 2.69 (q, J = 7.48 Hz, 2H), 1.21
(t, J = 7.52 Hz, 3H), 0.94−1.01 (m, 2H), 0.01−0.05 (m, 9H). To a
solution of [2-(4-bromo-5-ethyl-2-ﬂuorophenoxymethoxy)ethyl]-
trimethylsilane (105g, 300.6 mmol) in dioxane (1 L) were added
bis(pinacolato)diboron (76.4 g, 300.6 mmol) and potassium acetate
(88.5 g, 902 mmol). The resulting suspension was degassed with
nitrogen, Pd(dppf)Cl2 (24.54 g, 30.1 mmol) was added, and the
reaction was heated at reﬂux for 18 h. The reaction was cooled to
ambient temperature, and the solvent was removed in vacuo. The
resulting black solid was suspended in ethyl acetate (2 L) and ﬁltered
through Arbocel, washing with further ethyl acetate. The ﬁltrate was
washed with water (1.5 L) and brine (1.5 L), dried over anhydrous
magnesium sulfate, and concentrated in vacuo to give the title
compound 51 (155.5 g, 130%) that was used crude in the next step.
1H NMR (400 MHz, CDCl3) δ 7.47 (d, J = 12.10 Hz, 1H), 6.98−7.04
(m, 1H), 5.27 (s, 2H), 3.77−3.82 (m, 2H), 2.85 (q, J = 7.54 Hz, 2H),





Butyl Ester (54). To a solution of 48 (31.4 g, 59.5 mmol) in ethanol
(140 mL) was added a solution of 57 (US-2004/0229862, 18.02 g,
62.48 mmol) in ethanol (100 mL). Acetic acid (6.81 mL, 119 mmol)
was added, and the reaction mixture was heated at 50 °C for 18 h. The
reaction mixture was concentrated in vacuo and azeotroped with
toluene (100 mL) to give the title compound 54 (54.7 g, 117%) which
was used as is without further puriﬁcation. 1H NMR (400 MHz,
CDCl3) δ 8.23 (br s, 1H), 7.51 (br s, 1H), 7.32−7.43 (m, 2H), 7.18−
7.30 (m, 4H), 7.16 (d, J = 8.40 Hz, 1H), 7.04 (d, J = 11.52 Hz, 1H),
5.77 (br s, 1H), 5.31 (d, J = 8.20 Hz, 2H), 4.04 (t, J = 10.45 Hz, 1H),
3.82−3.92 (m, 2H), 3.48−3.82 (m, 7H), 2.81 (br s, 1H), 2.67 (br s,
3H), 2.55 (q, J = 7.42 Hz, 2H), 2.09−2.32 (m, 3H), 1.92 (br s, 2H),
1.65−1.84 (m, 3H), 1.14−1.24 (m, 5H), 1.10 (t, J = 7.52 Hz, 3H),
0.98−1.04 (m, 2H), 0.00−0.07 (m, 9H). LCMS found 784 [M + H]+.
5-Ethyl-2-ﬂuoro-4-[3-(4,5,6,7-tetrahydro-1H-imidazo[4,5-c]-
pyridin-2-yl)-1H-indazol-6-yl]phenol Dihydrochloric Acid Salt
(55). To a solution of 54 (46.65 g, 55.27 mmol) in ethanol (200 mL)
was added concentrated hydrochloric acid (12M, 100 mL, 1.2 mol),
and the resulting solution was stirred at ambient temperature for 18 h.
The reaction mixture was concentrated in vacuo and azeotroped with
toluene (100 mL) and dichloromethane (2 × 100 mL). The resulting
gum was dried under vacuum for 3 h. The crude material was
triturated in acetonitrile (300 mL), and the resulting solid was
collected by ﬁltration. The solid was dissolved in ethanol (250 mL)
and treated with concentrated hydrochloric acid (12 M, 77.2 mL, 927
mmol). The resulting solution was heated at 40 °C for 18 h, then at 50
°C for 2 h. The solvents were removed in vacuo, and the resulting gum
was triturated in acetonitrile (200 mL). The solid that formed was
collected by ﬁltration, washed with further acetonitrile (200 mL), and
dried under vacuum to give the title compound 55 (23.5 g, 88%
dihydrochloride salt). 1H NMR (400 MHz, CD3OD) δ 8.22 (d, J =
8.40 Hz, 1H), 7.59 (s, 1H), 7.33−7.41 (m, 1H), 6.95 (d, J = 11.52 Hz,
1H), 6.91 (d, J = 8.98 Hz, 1H), 4.56 (s, 2H), 3.73 (t, J = 6.05 Hz, 2H),
3.23 (t, J = 5.86 Hz, 2H), 2.53 (q, J = 7.61 Hz, 2H), 1.02−1.10 (m,
3H). LCMS found 378 [M + H]+.
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